

07 Feb 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.

This episode includes insights from around the biopharma world for the business week ended 5 February 2021.

This time we have views on, and progress with, [Pfizer Inc.](#) and [Johnson & Johnson](#)'s coronavirus vaccines, a delay for a closely-watched Alzheimer's drug, an interview with senior [Amgen, Inc.](#) executives, and more industry insiders' comments on key topics in the latest in the *Scrip Asks* series.

These and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and now on [Spotify Podcasts](#) - and also via smart speakers if one of these channels has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[COVID-19 Windfall Will Help Pfizer Remain Top Drug Company](#)" - Scrip, 2 Feb, 2021.)

(Also see "[J&J's One-Shot Vaccine Shows 66% Efficacy, But Company Says There's More To It](#)" - Scrip, 29 Jan, 2021.)

(Also see "[Aducanumab Approval Decision Delayed: Could This Be Good News?](#)" - Scrip, 29 Jan, 2021.)

(Also see "[While Amgen Sees Success For Two Growth Drivers, Headwinds Remain](#)" - Scrip, 1 Feb, 2021.)

(Also see "[Scrip Asks...What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care](#)"

- Scrip, 29 Jan, 2021.)

[Click here to explore this interactive content online](#) ✨